Botucatu Medical School, Clinics Hospital, Medical Physics and Radioprotection Nucleus, Botucatu, SP, Brazil.
Institute of Bioscience, Sao Paulo State University Julio de Mesquita Filho, Botucatu, SP, Brazil.
PLoS One. 2021 Jun 10;16(6):e0251783. doi: 10.1371/journal.pone.0251783. eCollection 2021.
In this work, we aimed to develop an automatic algorithm for the quantification of total volume and lung impairments in four different diseases. The quantification was completely automatic based upon high resolution computed tomography exams. The algorithm was capable of measuring volume and differentiating pulmonary involvement including inflammatory process and fibrosis, emphysema, and ground-glass opacities. The algorithm classifies the percentage of each pulmonary involvement when compared to the entire lung volume. Our algorithm was applied to four different patients groups: no lung disease patients, patients diagnosed with SARS-CoV-2, patients with chronic obstructive pulmonary disease, and patients with paracoccidioidomycosis. The quantification results were compared with a semi-automatic algorithm previously validated. Results confirmed that the automatic approach has a good agreement with the semi-automatic. Bland-Altman (B&A) demonstrated a low dispersion when comparing total lung volume, and also when comparing each lung impairment individually. Linear regression adjustment achieved an R value of 0.81 when comparing total lung volume between both methods. Our approach provides a reliable quantification process for physicians, thus impairments measurements contributes to support prognostic decisions in important lung diseases including the infection of SARS-CoV-2.
在这项工作中,我们旨在开发一种自动算法,用于量化四种不同疾病的总容积和肺部损伤。定量完全基于高分辨率计算机断层扫描检查实现自动化。该算法能够测量体积,并区分肺部受累,包括炎症过程和纤维化、肺气肿和磨玻璃影。该算法将每种肺部受累与整个肺容积进行分类。我们的算法应用于四个不同的患者群体:无肺部疾病患者、诊断为 SARS-CoV-2 的患者、慢性阻塞性肺疾病患者和球孢子菌病患者。定量结果与以前验证的半自动算法进行了比较。结果证实,自动方法与半自动方法具有良好的一致性。Bland-Altman(B&A)分析表明,在比较总肺容积和比较每个肺损伤时,散度都较低。当比较两种方法的总肺容积时,线性回归调整达到 0.81 的 R 值。我们的方法为医生提供了一种可靠的定量过程,因此损伤测量有助于支持包括 SARS-CoV-2 感染在内的重要肺部疾病的预后决策。